The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C10 | Lipid modifying agents | |
| 3 | C10B | Lipid modifying agents, combinations | |
| 4 | C10BA | Combinations of various lipid modifying agents | |
| 5 | C10BA03 | Pravastatin and fenofibrate |
| Active Ingredient | Description | |
|---|---|---|
| Pravastatin and Fenofibrate |
Pravastatin and fenofibrate, which have different modes of action, show additive effects in terms of reduction of serum lipid. Pravastatin is more effective in reducing LDL-C and total cholesterol but presents only modest effects on TG and HDL-C while fenofibrate is very effective in decreasing TG and increasing HDL-C, but with few effects on LDL-C. Additionally, fibrates have the properties to modify the size and density of LDL-C particles to make them less atherogenic. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| PRAVAFEN Hard capsule | Health Sciences Authority (SG) | MPI, Generic | |
| PRAVAFENIX Hard capsule | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
